Home E3 Ligand Plus Linker (Lenalidomide)
Lenalidomide, an immunomodulatory drug, has received approval in the United States for its use alongside rituximab in patients with relapsed/refractory follicular lymphoma. We examined data from trials evaluating the safety and efficacy of lenalidomide, both as a standalone treatment and in combination with rituximab, for both first-line therapy and for treating patients with relapsed/refractory follicular lymphoma. Lenalidomide-rituximab has proven to be an effective chemotherapy-free therapy, surpassing the efficacy of single-agent rituximab. It holds the potential to serve as an alternative to chemoimmunotherapy.
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :